Long acting GLP-1 receptor agonist (injectable)
Dulaglutide 0.25 mg injection once weekly
DULA_SC_0p25MG_QW
Related
- All doses pooled: Dulaglutide injection
- Dulaglutide 1.0 mg injection once weekly
- Dulaglutide 1.5 mg subcutaneous once weekly
- Dulaglutide 3.0 mg subcutaneous once weekly
- Dulaglutide 4.5 mg subcutaneous once weekly
- Dulaglutide 0.5 mg injection once weekly
- Dulaglutide 0.75 mg subcutaneous once weekly
- Dulaglutide flexible dose injection once weekly
- Dulaglutide 2.0 mg injection once weekly
- Dulaglutide 0.1 mg injection once weekly
- Dulaglutide 0.75 mg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.58 (0.01 to 45.07) | 0.45 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.18 (0.00 to 3.43) | 0.85 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.92 (0.11 to 24.97) | 0.33 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.92 (0.06 to 7.97) | 0.63 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.12 (0.00 to 1.37) | 0.93 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.32 (0.00 to 9.54) | 0.81 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.80 (0.06 to 5.84) | 0.69 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.18 (0.00 to 2.81) | 0.86 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.63 (0.01 to 47.95) | 0.63 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.85 (0.05 to 13.47) | 0.47 |